针对WHO重要真菌优先病原体的新治疗选择
该综述聚焦WHO 2022年真菌优先病原体清单中Critical组的烟曲霉、白色念珠菌、耳念珠菌和新型隐球菌,基于PubMed文献检索梳理新型抗真菌药物(包括ibrexafungerp、rezafungin、fosmanogepix、olorofim等)的近期临床试验数据与治疗进展,并讨论耐药挑战与抗真菌药物管理。
要点
- WHO 2022年将烟曲霉、白色念珠菌、耳念珠菌和新型隐球菌列入Critical组。
- ibrexafungerp、oteseconazole和rezafungin已获FDA批准,olorofim和fosmanogepix预计未来数年获批。
- ibrexafungerp、fosmanogepix和rezafungin获欧洲药品管理局孤儿药资格。
核心结论
- 尽管靶点有限和耐药出现给抗真菌治疗带来挑战,ibrexafungerp、rezafungin、fosmanogepix或olorofim等新药已显示出有前景的临床疗效。
- 这些药物不仅为侵袭性真菌感染提供替代选择,还减轻门诊治疗负担。
- 需要更多临床数据、抗真菌药物管理项目实施和监测(包括农业中药物使用)来防止耐药发展并确保新药安全有效。
研究设计与样本
- 综述,通过PubMed检索烟曲霉、新型隐球菌、耳念珠菌和白色念珠菌以及fosmanogepix、ibrexafungerp、opelconazole、oteseconazole、MAT2203、olorofim和rezafungin等新型抗真菌药物名称的文献。
主要发现
- ibrexafungerp于2021年6月获FDA批准,oteseconazole于2022年4月获FDA批准,rezafungin于2023年3月获FDA批准。
- olorofim和fosmanogepix预计在未来数年获得批准。
- ibrexafungerp于2021年11月、fosmanogepix于2022年7月、rezafungin于2024年1月获欧洲药品管理局孤儿药资格。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Yet often overlooked in public health discourse, fungal infections pose a crucial global disease burden associated with annual mortality rates approximately equal to tuberculosis and HIV. In response, the WHO published its first global priority list of fungal pathogens in 2022 assigning Aspergillus fumigatus, Candida albicans, Candida auris, and Cryptococcus neoformans to the critical group. OBJECTIVES: This review provides succinct insights into novel antifungals in development, aiming to contribute valuable information and perspectives with a focus on recent clinical findings and new treatment approaches for critical members of the WHO fungal pathogen priority list. SOURCES: PubMed literature search using 'Aspergillus fumigatus', 'Cryptococcus neoformans', 'Candida auris', and 'Candida albicans', along with the names of novel antifungal substances, including 'fosmanogepix', 'ibrexafungerp', 'opelconazole', 'oteseconazole', 'MAT2203', 'olorofim', and 'rezafungin' was conducted. CONTENT: For each critical pathogen, current issues and global clinical data from recent trials are covered. The remarkable development of three new antifungal therapeutics recently receiving Food and Drug Administration approval (ibrexafungerp-June 2021, oteseconazole -April 2022, and rezafungin-March 2023) is outlined, with two more exciting new antifungal substances, namely, olorofim and fosmanogepix expecting approval within the next years. Ibrexafungerp, fosmanogepix, and rezafungin have additionally been granted orphan drug status by the European Medicines Agency in Europe (ibrexafungerp-November 2021, fosmanogepix-July 2022, and rezafungin-January 2024). IMPLICATIONS: Although the limited number of targets and the emergence of resistance have posed challenges to antifungal treatment, new drugs such as ibrexafungerp, rezafungin, fosmanogepix, or olorofim have shown promising clinical efficacy. These drugs not only provide alternative options for invasive fungal infections but also alleviate treatment in outpatient settings. More clinical data, implementation of stewardship programmes, and surveillance, including utilization of drugs in agriculture, are necessary to prevent resistance development and to ensure the safety and efficacy of these new agents.
引用
- Kriegl L, Egger M, Boyer J, et al. New treatment options for critically important WHO fungal priority pathogens. Clin Microbiol Infect. 2024. PMID: 38461942. doi:10.1016/j.cmi.2024.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。